| 01.07 08:01 | dpa-AFX: *SANDOZ VORBÖRSLICH +2,6% - US-ZULASSUNG FÜR BIOSIMILAR |
| 01.07 07:28 | dpa-AFX: Sandoz erhält US-Zulassung für Schuppenflechte-Biosimilar Pyzchiva |
| 01.07 07:00 | Press Release: FDA approves biosimilar Pyzchiva(R) (ustekinumab-ttwe), to be commercialized by Sandoz in US |
| 01.07 07:00 | Press Release: FDA approves biosimilar -2- |
| 01.07 07:00 | dpa-AFX: GNW-Adhoc: FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US |
| 22.05 17:41 | Aktien Schweiz erneut mit Abgaben - SMI wieder unter 12.000 Punkten |
| 22.05 15:53 | MÄRKTE EUROPA/Knapp behauptet - Autosektor mit Sorgen vor China-Zöllen schwach |
| 22.05 13:06 | MÄRKTE EUROPA/Etwas leichter vor Fed-Protokoll |
| 22.05 10:02 | MÄRKTE EUROPA/Inflationsdaten bremsen - Blick auf Fed und Nvidia |
| 22.05 07:00 | Press Release: Sandoz receives European Commission approval for Wyost(R) and Jubbonti(R), the first and only biosimilars of denosumab in Europe |
| 22.05 07:00 | dpa-AFX: GNW-Adhoc: Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe |
| 07.05 17:49 | Aktien Schweiz deutlich im Plus - UBS nach Zahlen sehr fest |
| 07.05 07:00 | dpa-AFX: GNW-Adhoc: Sandoz reports first quarter 2024 sales |
| 07.05 07:00 | Press Release: Sandoz reports first quarter 2024 sales |
| 07.05 07:00 | Press Release: Sandoz reports first quarter 2024 -2- |
| 30.04 12:25 | dpa-AFX: GNW-Adhoc: Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG |
| 30.04 12:25 | Press Release: Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG |
| 30.04 07:00 | Press Release: Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars |
| 30.04 07:00 | Press Release: Sandoz reaches agreement with -2- |
| 30.04 07:00 | dpa-AFX: GNW-Adhoc: Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars |
|
|
